MWA
NKTR icon

Medallion Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Medallion Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$935 – 1280
2026
Q1 		$935 Hold
13
– – ﹤0.01% 1063
2025
Q4 		$550 Hold
13
– – ﹤0.01% 1072
2025
Q3 		$740 Hold
13
– – ﹤0.01% 1049
2025
Q2 		$336 Sell
13
-1
-7% -$11 ﹤0.01% 1058
2025
Q1 		$141 Hold
14
– – ﹤0.01% 1048
2024
Q4 		$141 Buy
+14
New +$247 ﹤0.01% 991

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Medallion Wealth Advisors's NKTR Position: Q2 2026 in Review

Medallion Wealth Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 13 shares — an estimated $935 sold.

Medallion Wealth Advisors first reported a position in NKTR in Q4 2024 and held it in 6 quarters. The position peaked at $935 in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Medallion Wealth Advisors reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Medallion Wealth Advisors sold 13 Nektar Therapeutics shares in Q2 2026, an estimated $935.
  • Medallion Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2024 and held it in 6 quarters.
  • Medallion Wealth Advisors's Nektar Therapeutics position peaked at $935 in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.